199 related articles for article (PubMed ID: 30498064)
1. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.
Koch R; Christie AL; Crombie JL; Palmer AC; Plana D; Shigemori K; Morrow SN; Van Scoyk A; Wu W; Brem EA; Secrist JP; Drew L; Schuller AG; Cidado J; Letai A; Weinstock DM
Blood; 2019 Feb; 133(6):566-575. PubMed ID: 30498064
[TBL] [Abstract][Full Text] [Related]
2. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
3. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
[TBL] [Abstract][Full Text] [Related]
4. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma.
Magni M; Biancon G; Rizzitano S; Cavanè A; Paolizzi C; Dugo M; Corradini P; Carniti C
Br J Cancer; 2019 Oct; 121(7):567-577. PubMed ID: 31474759
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
7. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Moujalled DM; Pomilio G; Ghiurau C; Ivey A; Salmon J; Rijal S; Macraild S; Zhang L; Teh TC; Tiong IS; Lan P; Chanrion M; Claperon A; Rocchetti F; Zichi A; Kraus-Berthier L; Wang Y; Halilovic E; Morris E; Colland F; Segal D; Huang D; Roberts AW; Maragno AL; Lessene G; Geneste O; Wei AH
Leukemia; 2019 Apr; 33(4):905-917. PubMed ID: 30214012
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
9. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
10. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
[TBL] [Abstract][Full Text] [Related]
11. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.
Quentmeier H; Geffers R; Hauer V; Nagel S; Pommerenke C; Uphoff CC; Zaborski M; Drexler HG
Sci Rep; 2022 Jan; 12(1):1085. PubMed ID: 35058488
[TBL] [Abstract][Full Text] [Related]
13. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.
Cayrol F; Praditsuktavorn P; Fernando TM; Kwiatkowski N; Marullo R; Calvo-Vidal MN; Phillip J; Pera B; Yang SN; Takpradit K; Roman L; Gaudiano M; Crescenzo R; Ruan J; Inghirami G; Zhang T; Cremaschi G; Gray NS; Cerchietti L
Nat Commun; 2017 Jan; 8():14290. PubMed ID: 28134252
[TBL] [Abstract][Full Text] [Related]
14. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
S Soderquist R; Eastman A
Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling.
Surman DR; Xu Y; Lee MJ; Trepel J; Brown K; Ramineni M; Splawn TG; Diggs LP; Hodges HC; Davis JL; Lee HS; Burt BM; Ripley RT
Mol Cancer Ther; 2021 Aug; 20(8):1469-1480. PubMed ID: 34088830
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
[No Abstract] [Full Text] [Related]
17. AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death.
Jia J; Ji W; Saliba AN; Csizmar CM; Ye K; Hu L; Peterson KL; Schneider PA; Meng XW; Venkatachalam A; Patnaik MM; Webster JA; Smith BD; Ghiaur G; Wu X; Zhong J; Pandey A; Flatten KS; Deng Q; Wang H; Kaufmann SH; Dai H
Cell Death Differ; 2024 Apr; 31(4):405-416. PubMed ID: 38538744
[TBL] [Abstract][Full Text] [Related]
18. BCL2 and MCL1 inhibitors for hematologic malignancies.
Roberts AW; Wei AH; Huang DCS
Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
[TBL] [Abstract][Full Text] [Related]
19. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
[TBL] [Abstract][Full Text] [Related]
20. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
